Coagadex (Coagulation Factor X [Human]) for Haemophilia

Overview
Coagadex is approved by the U.S. Food and Drug Administration (FDA) for use in adults and children with hereditary factor X (10) deficiency. It is indicated for routine prophylaxis to reduce bleeding episodes, for on-demand treatment and control of bleeding, and for bleeding management during surgery in people with mild, moderate, or severe deficiency. Coagadex is also known by its drug name, coagulation factor X (human).

Coagadex is a plasma-derived clotting factor replacement therapy. It works by supplementing the body’s missing or deficient factor X, which is essential for blood clotting. By restoring factor X levels, Coagadex is believed to help prevent and control bleeding in people with this rare bleeding disorder.

How do I take it?
Prescribing information states that Coagadex is given as an intravenous (IV) infusion after reconstitution. For routine prophylaxis, children under 12 typically receive it twice weekly at a higher dose than adults and adolescents, who also receive it twice weekly. For treating bleeding episodes, it is generally given at the first sign of bleeding and may be repeated every 24 hours until bleeding stops. In surgical settings, doses are adjusted to achieve target factor X levels before and after surgery. The drug should always be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Coagadex include infusion site erythema (discoloration), infusion site pain, fatigue, and back pain.

Rare but serious side effects may include anaphylaxis (life-threatening allergic reactions), the development of neutralizing antibodies (which can make the treatment less effective), and the risk of transmitting infectious agents such as viruses or the agents that cause Creutzfeldt-Jakob disease, since the product is made from human blood.

For more information about this treatment, visit:
Label: Coagadex- Coagulation Factor X Human Kit — DailyMed